Philadelphia, United States
Context Therapeutics, operating under the slogan "Advancing T Cell Engagers for Solid Tumors," is making waves in the biotechnology and health care sectors. Founded in 2015 and headquartered in the United States, the company focuses on developing innovative T cell engaging (TCE) bispecific antibodies to target solid tumors.
The company's pipeline includes promising candidates like CTIM-76 (Claudin 6 x CD3), CT-95 (Mesothelin x CD3), and CT-202 (Nectin-4 x CD3), showcasing its strong portfolio in TCE bispecific therapeutics. Context's approach leverages cutting-edge biopharmaceutical advances to tackle challenging oncological needs.
Context recently secured a significant $100.00M post-IPO equity investment on 02 May 2024. This fundraise was led by prominent investors like Blackstone Group, Ally Bridge Group, and Deep Track Capital, among others, signaling strong confidence in its growth potential and therapeutic promise.
